双释放氢化可的松改善艾迪生病患者尿皮质醇代谢组:一项前瞻性试验
这项随机12周交叉研究比较了每日一次双释放氢化可的松(DR-HC)与每日三次常规氢化可的松(TID-HC)对原发性肾上腺功能不全患者(n=50)尿皮质醇代谢组的影响,并与健康对照(n=124)比较。结果显示DR-HC使总皮质醇代谢物降低至对照水平,并改善11β-HSD1和11β-HSD2活性,提示DR-HC可能通过调节皮质醇代谢介导代谢益处。
要点
- DR-HC较TID-HC降低总皮质醇代谢物并达到对照水平。
- DR-HC降低11β-HSD1活性并正常化11β-HSD2活性。
- 尿皮质醇代谢组或可用于评估氢化可的松替代治疗是否 optimal。
核心结论
- 常规TID-HC治疗患者尿皮质醇代谢组存在显著异常,11β-HSD1活性增加可能解释不利代谢表型。
- DR-HC使代谢组趋向正常化,可能介导有益代谢效应。
- 尿皮质醇代谢组可作为评估最佳皮质醇替代治疗的工具。
研究设计与样本
- 随机、12周、交叉研究。
- 原发性肾上腺功能不全患者(n=50)接受DR-HC和相同日剂量TID-HC,健康个体(n=124)作为对照。
主要发现
- DR-HC相比TID-HC总皮质醇代谢物降低(P < .001),达到对照值(P = .089)。
- DR-HC相比TID-HC,11β-HSD1活性(四氢皮质醇+5α-四氢皮质醇/四氢可的松比值)降低(P < .05),但仍高于对照(P < .001)。
- 11β-HSD2活性(尿游离可的松/游离皮质醇比值)在TID-HC相比对照降低(P < .01),DR-HC时正常化(P = .358)。
- DR-HC相比TID-HC,5α-和5β-还原代谢物降低。
- 两种治疗期间四氢皮质醇/5α-四氢皮质醇比值均增加,提示5β-还原酶活性增加。
临床怎么用
- 对于原发性肾上腺功能不全患者,DR-HC可能改善皮质醇代谢组,但需结合临床评估。
- 尿皮质醇代谢组或可作为监测替代治疗是否 optimal 的潜在工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy has demonstrated an improved metabolic profile compared to conventional 3-times-daily (TID-HC) therapy among patients with primary adrenal insufficiency. This effect might be related to a more physiological cortisol profile, but also to a modified pattern of cortisol metabolism. OBJECTIVE: This work aimed to study cortisol metabolism during DR-HC and TID-HC. DESIGN: A randomized, 12-week, crossover study was conducted. INTERVENTION AND PARTICIPANTS: DC-HC and same daily dose of TID-HC were administered to patients with primary adrenal insufficiency (n = 50) vs healthy individuals (n = 124) as controls. MAIN OUTCOME MEASURES: Urinary corticosteroid metabolites were measured by gas chromatography/mass spectrometry at 24-hour urinary collections. RESULTS: Total cortisol metabolites decreased during DR-HC compared to TID-HC (P < .001) and reached control values (P = .089). During DR-HC, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity measured by tetrahydrocortisol + 5α-tetrahydrocortisol/tetrahydrocortisone ratio was reduced compared to TID-HC (P < .05), but remained increased vs controls (P < .001). 11β-HSD2 activity measured by urinary free cortisone/free cortisol ratio was decreased with TID-HC vs controls (P < .01) but normalized with DR-HC (P = .358). 5α- and 5β-reduced metabolites were decreased with DR-HC compared to TID-HC. Tetrahydrocortisol/5α-tetrahydrocortisol ratio was increased during both treatments, suggesting increased 5β-reductase activity. CONCLUSIONS: The urinary cortisol metabolome shows striking abnormalities in patients receiving conventional TID-HC replacement therapy, with increased 11β-HSD1 activity that may account for the unfavorable metabolic phenotype in primary adrenal insufficiency. Its change toward normalization with DR-HC may mediate beneficial metabolic effects. The urinary cortisol metabolome may serve as a tool to assess optimal cortisol replacement therapy.
引用
- Espiard S, McQueen J, Sherlock M, et al. Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone. J Clin Endocrinol Metab. 2021. PMID: 33236103. doi:10.1210/clinem/dgaa862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。